TY  - GEN
AU  - Dafni, U.
AU  - Soo, R. A.
AU  - Peters, S.
AU  - Tsourti, Z.
AU  - Zygoura, P.
AU  - Vervita, K.
AU  - Han, J-Y
AU  - De Castro, J.
AU  - Coate, L.
AU  - Fruh, M.
AU  - Hashemi, S. M. S.
AU  - Nadal, E.
AU  - Carcereny, E.
AU  - Sala, M. A.
AU  - Bernabe, R.
AU  - Provencio, M.
AU  - Cuffe, S.
AU  - Roschitzki-Voser, H.
AU  - Ruepp, B.
AU  - Rosell, R.
AU  - Stahel, R. A.
PY  - 2022
DO  - 10.1016/j.esmoop.2022.100507
UR  - http://hdl.handle.net/10668/22216
T2  - Esmo open
AB  - Background: The ETOP 10-16 BOOSTER trial failed to demonstrate a progression-free survival (PFS) benefit for adding bevacizumab to osimertinib in second line. An exploratory subgroup analysis, however, suggested a PFS benefit of the combination in...
LA  - en
PB  - Elsevier
KW  - EGFR mutations
KW  - NSCLC
KW  - EGFR-TKI
KW  - randomised controlled trial
KW  - smoking status
KW  - Cell lung-cancer
KW  - Plus bevacizumab
KW  - Mutations
KW  - Erlotinib
KW  - Osimertinib
KW  - Multicenter
KW  - Monotherapy
KW  - Survival
TI  - Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis
TY  - review
VL  - 7
ER  -